Keyword: Office of Prescription Drug Promotion
The FDA OPDP slapped a warning letter on Mannkind for failing to mention Afrezza's risks.
The FDA's promo police are back in action with their fourth untitled letter of the year—and it's a second for Ascend Therapeutics.
The FDA's ad police have sent Collegium Pharmaceuticals their first letter of the year. And it tackles a hot-topic category: opioids.